Skip to content

Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease

Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06575660
Enrollment
22
Registered
2024-08-28
Start date
2024-09-23
Completion date
2025-10-09
Last updated
2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Crohn Disease, Depression, Inflammatory Bowel Diseases, Ulcerative Colitis

Brief summary

This is a small, exploratory study that will investigate using an artificial intelligence (AI) and virtual reality (VR), digital wellness application (app) to deliver a mental health support session in outpatient and hospitalized patients with inflammatory bowel disease (IBD) and co-existing symptoms of mild to moderate anxiety or depression. The purpose of this study is to explore if a mental health support session using the app is feasible, safe, and acceptable to IBD patients and whether it could possibly help with physical and comorbid psychological symptoms of these patients.

Detailed description

The mental health support session is delivered by a virtual reality digital wellness application (app). The app is a Chat GPT-4 powered AI and VR platform called XAIA (eXtended reality Artificially Intelligent Ally). \[Chat GPT is an AI program that generates dialogue.\] The app is publicly available on the Apple Vision Pro (a VR tool). It was developed by a group of providers, including a psychiatrist, at Cedars-Sinai Medical Center to devise a scalable solution for the increasing demand for mental wellness experiences. The application uses the combination of an AI-powered virtual avatar, named XAIA, and a VR environment to deliver immersive and personalized mental health support in mixed-reality environments. This is a mixed method study with primarily a qualitative focus. Patients with IBD who self-report mild to moderate levels of anxiety or depression will be invited to try a single AI-VR mental health support session using the XAIA app. Participant observations, experiences, and opinions of the application will be collected through surveys and semi-structured interviews. Pre- and post- session pain and state anxiety scores will be collected.

Interventions

BEHAVIORALMental health support session

a single AI-VR mental health support session using the XAIA application

Sponsors

Cedars-Sinai Medical Center
CollaboratorOTHER
University of Chicago
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18+ years of age * Patients with Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) * English-speaking * Patients with score of 5-14 on General Anxiety Disorder-7 (GAD-7) questionnaire or 5-19 on Patient Health Questionnaire-9 (PHQ-9) within 3 months * Able to provide written consent

Exclusion criteria

* Unwilling and/or unable to participate * Non-English speakers * Self-reported history of severe motion sickness * The presence of a facial/head deformity that will prohibit comfortably wearing of a VR headset * Legally blind or deaf * Having had a seizure in the past year * Unable to understand the instructions or to consent to participation in the study. * Those who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Determine the feasibility of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBDDay 1 post-sessionMeasured via a post-session, semi-structured interview
Determine the safety of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBDDay 1 post-sessionMeasured by proportion of subjects with at least one adverse event
Determine the patient acceptance of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBDDay 1 post-sessionMeasured via Session Rating Scale (SRS V.3.0), which is a visual analogue scale that measures self-reported effective therapeutic relationships. Scores range from 0 to 40, with higher scores indicating more effective relationships. Scores are commonly classified as any score lower than 36 overall, or 9 on any \[of the 4\] scale\[s\], could be a source of concern...

Secondary

MeasureTime frameDescription
To assess change in pain scores pre- and post-sessionDay 1 pre-session; Day 1 post-sessionMeasured via Visual Analogue Pain Scale, which is a scale that measures self-reported pain intensity. Scores range from 0-10, with higher scores indicating greater pain intensity. Scores are commonly classified as no pain (0), mild pain (1-3), moderate to severe pain (4-6), very severe pain (7-9), worst possible pain (10).
To characterize any potential future improvements for creating a AI-VR mental health support tool optimally aligned with the needs of patients with IBDDay 1 post-sessionMeasured via a post-session, semi-structured interview
To assess change in mood scores pre- and post-sessionDay 1 pre-session; Day 1 post-sessionSpielberger State-Trait Anxiety Inventory (STAI), which is a tool that measures self-reported anxiety. Scores range from 0-40, with higher scores indicating greater anxiety. STAI scores are commonly classified as no or low anxiety (20-37), moderate anxiety (38-44), and high anxiety (45-80).
To characterize any limitations for creating a AI-VR mental health support tool optimally aligned with the needs of patients with IBDDay 1 post-sessionMeasured via a post-session, semi-structured interview

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026